Greg Guilcher

Gregory Guilcher

MD
Pronouns: He/him

Positions

Associate Professor

Cumming School of Medicine, Department of Oncology

Associate Professor

Cumming School of Medicine, Department of Pediatrics

Childhood Cancer & Blood Disorders Program Director

Alberta Children's Hospital Research Institute

Child Health & Wellness Researcher

Alberta Children's Hospital Research Institute

Member

Arnie Charbonneau Cancer Institute

Contact information

Web presence

Phone number

Office- research inquiries only: 403.955.7272

For media enquiries, contact

Kelly Johnston
Senior Communications Specialist

Please submit your media request here

 

Preferred method of communication

Admin Assistant

Karen Fandrey

Email: karen.fandrey@ahs.ca

Office: 403.955.7272

Background

Credentials

FRCPC, Royal College of Physicians and Surgeons of Canada, 2005

FAAP, American Academy of Pediatrics, 2005

DRCPSC in HSCT-Cellular Therapy, Royal College of Physicians and Surgeons of Canada, 2023

Certification in Pediatrics, Royal College of Physicians and Surgeons of Canada, 2005

Certification in Hematology, Royal College of Physicians and Surgeons of Canada, 2007

Certification in Pediatric Hematology/Oncology, Royal College of Physicians and Surgeons of Canada, 2008

Certification in Pediatrics, American Board of Pediatrics, 2005

Certification in Pediatric Hematology/Oncology, American Board of Pediatrics, 2011

Educational Background

B.Sc. Biochemistry, Queen's University, 1997

Doctor of Medicine, Memorial University of Newfoundland, 2001

Postgraduate Certificate Medical Education, University of Dundee, 2011

Fellowship Pediatric Hematology/Oncology, University of British Columbia, 2007

Residency Pediatrics, Memorial University of Newfoundland, 2004

Biography

Chair of the Children’s Oncology Group HCT-CT/Dermatology/Immunology Late Effects Taskforce, Chair of the Royal College Pediatric Hematology/Oncology Examination Committee, Program Director for Childhood Cancer and Blood Disorders for the Alberta Children’s Hospital Research Institute, Co-Chair of the Hemoglobinopathy Working Committee for Cell Therapy Transplant Canada, Pediatric Transplantion and Cellular Therapy Consortium Hemoglobinopathy Steering Committee 

Research

Areas of Research

Cancer

Acute and late toxicities of therapy, including pharmacogenomic testing to predict and prevent toxicity. Immune recovery after childhood cancer therapy.

Novel Therapeutics

Dr. Guilcher is a site investigator for several Phase I, II and III studies.

Transplantation

Hematopoietic cell transplantation (HCT) for malignant and non-malignant diseases, with a special interest in sickle cell disease. Chair of the HCT-CT/Immune/Dermatology Late Effects Taskforce for the Children's Oncology Group.

Summary of Research

Research interests include acute and late toxicities of childhood cancer therapy and HCT as well as the study of novel low-toxicity approaches to transplant for pediatric non-malignant diseases. Greg is interested in studying family HCT decision-making , neuropsychological outcomes and health economics questions as related to HCT for sickle cell disease. He also has an interest in pediatric HCT donor safety. A career goal is to expand access to HCT for sickle cell disease to low and middle income countries.

 

Participation in university strategic initiatives

Projects

Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease (SUN)

Co-Principal Investigator of this multi-site international clinical trial using the NIH nonmyeloablative regimen for matched sibling donor HCT in children and adolescents with sickle cell disease.


Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY (SUN-RAY)

Co-Principal Investigator of this multi-site clinical trial using daratumumab prior to conditioning with the NIH nonmyeloablative regimen for sickle cell disease when recipients have donor-directed red blood cell antibodies.


Project Sickle Cure

Principal Investigator of this international multi-site prospective registry of HCT outcomes for sickle cell disease.


Comparative Effectiveness of MRD HCT and NT-DMT for Pediatric Sickle Cell Disease (WeDecide)

Co-Principal Investigator of this international study comparing outcomes of HCT for sickle cell disease with disease-modifying therapies.

Awards

  • Researcher of the Year, Department of Pediatrics, University of Calgary. 2018
  • President's Excellence Award- Outstanding Achievement in Innovation and Research, Alberta Health Services. 2018
  • Gold Lego Teaching Award, Department of Pediatrics , University of Calgary PGME. 2021